Cipla was founded in Bombay in 1935, and released its first products in 1937. The company first gained US FDA approval for its bulk drug facilities in 1985. The company has seven facilities in India and is planning an eighth.
Sales for fiscal 2008 amounted to Rs43.4 billion, crossing the US$1 billion threshold for the first time. Revenues to Africa accounted for 34% of the total. Revenues attributed to Cipla's sales of tablets and capsules were worth Rs23.1 billion, a rise of 14.5% over fiscal 2007.
Cipla manufactures APIs and formulation drugs, and its products are sold in over 150 countries. A number of the company's dosage forms and APIs are approved by regulatory agencies including the US FDA, the UK MHRA, Germany's PIC, South Africa's MCC, Australia's TGA, Health Canada and the WHO.
Cipla claims to have been the first local manufacturer to introduce a number of products to the Indian market, including the antiretrovirals zidovudine, stavudine, lamivudine and nevirapine. Other firsts have included propranolol, ondansetron, salmeterol, montelukast, fluticasone propionate and doxazosin.
Cipla gained global recognition in 2001 when it offered to export anti-AIDS drug for less than US$1 a day, and the company remains at the forefront of this business. Cipla has, however, recently run into controversy over its AIDS drug pricing in India and elsewhere.
In June 2008, Cipla gained US FDA approval for its zidovudine oral solution, and tentative approval for its lamivudine and stavudine fixed-dose combination tablet.
These generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the companys active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Key Topics Covered:
Executive Summary
Introduction
Recent product approvals
Financial results
Major developments
Mergers, acquisitions and agreements
Litigation
Contact Details
Companies Mentioned:
Akorn
Enaleni
Pentech Pharmaceuticals
Avestha Gengraine Technologies
Morton Grove Pharmaceuticals
Watson Pharmaceuticals
Stada
Hexal
Fujisawa
No comments:
Post a Comment